HETEROSEXUAL TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VARIANTS ASSOCIATED WITH ZIDOVUDINE RESISTANCE

被引:66
作者
CONLON, CP
KLENERMAN, P
EDWARDS, A
LARDER, BA
PHILLIPS, RE
机构
[1] JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND
[2] JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,INFECT DIS UNIT,OXFORD OX3 9DU,ENGLAND
[3] RADCLIFFE INFIRM,DEPT GENITOURINARY MED,OXFORD,ENGLAND
[4] WELLCOME RES LABS,DIV MOLEC SCI,BECKENHAM,KENT,ENGLAND
基金
英国惠康基金;
关键词
D O I
10.1093/infdis/169.2.411
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
During zidovudine therapy, human immunodeficiency virus type 1 (HIV-1) acquires a distinctive set of mutations that diminish the sensitivity of the virus to this drug in vitro. An AIDS patient is described who, while being treated with zidovudine, transmitted HIV-1 bearing a drug resistance mutation to a young woman who had never received zidovudine treatment. DNA sequencing of HIV-1 proviruses confirmed that these 2 persons shared HIV genetic variants, including a mutation at codon 70 in the reverse transcriptase gene associated with reduced in vitro sensitivity to zidovudine. This mutation persisted in the woman > 1 year in the absence of antiretroviral therapy. HIV-1 with genetic markers of zidovudine resistance can be transmitted heterosexually, but it is uncertain whether dissemination of drug-resistant virus will substantially reduce the usefulness of this drug.
引用
收藏
页码:411 / 415
页数:5
相关论文
共 15 条
[1]   PRELIMINARY-ANALYSIS OF THE CONCORDE TRIAL [J].
ABOULKER, JP ;
SWART, AM .
LANCET, 1993, 341 (8849) :889-890
[2]   ORDERED APPEARANCE OF ZIDOVUDINE RESISTANCE MUTATIONS DURING TREATMENT OF 18 HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE SUBJECTS [J].
BOUCHER, CAB ;
OSULLIVAN, E ;
MULDER, JW ;
RAMAUTARSING, C ;
KELLAM, P ;
DARBY, G ;
LANGE, JMA ;
GOUDSMIT, J ;
LARDER, BA .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (01) :105-110
[3]   BRIEF REPORT - PRIMARY INFECTION WITH ZIDOVUDINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
ERICE, A ;
MAYERS, DL ;
STRIKE, DG ;
SANNERUD, KJ ;
MCCUTCHAN, FE ;
HENRY, K ;
BALFOUR, HH .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (16) :1163-1165
[4]   THE EFFICACY OF AZIDOTHYMIDINE (AZT) IN THE TREATMENT OF PATIENTS WITH AIDS AND AIDS-RELATED COMPLEX - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
FISCHL, MA ;
RICHMAN, DD ;
GRIECO, MH ;
GOTTLIEB, MS ;
VOLBERDING, PA ;
LASKIN, OL ;
LEEDOM, JM ;
GROOPMAN, JE ;
MILDVAN, D ;
SCHOOLEY, RT ;
JACKSON, GG ;
DURACK, DT ;
KING, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (04) :185-191
[5]   THE EFFECTS ON SURVIVAL OF EARLY TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
GRAHAM, NMH ;
ZEGER, SL ;
PARK, LP ;
VERMUND, SH ;
DETELS, R ;
RINALDO, CR ;
PHAIR, JP .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (16) :1037-1042
[6]   5TH MUTATION IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE CONTRIBUTES TO THE DEVELOPMENT OF HIGH-LEVEL RESISTANCE TO ZIDOVUDINE [J].
KELLAM, P ;
BOUCHER, CAB ;
LARDER, BA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (05) :1934-1938
[7]   HIV WITH REDUCED SENSITIVITY TO ZIDOVUDINE (AZT) ISOLATED DURING PROLONGED THERAPY [J].
LARDER, BA ;
DARBY, G ;
RICHMAN, DD .
SCIENCE, 1989, 243 (4899) :1731-1734
[8]   MULTIPLE MUTATIONS IN HIV-1 REVERSE-TRANSCRIPTASE CONFER HIGH-LEVEL RESISTANCE TO ZIDOVUDINE (AZT) [J].
LARDER, BA ;
KEMP, SD .
SCIENCE, 1989, 246 (4934) :1155-1158
[9]   QUANTITATION OF ZIDOVUDINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN THE BLOOD OF TREATED AND UNTREATED PATIENTS [J].
MOHRI, H ;
SINGH, MK ;
CHING, WTW ;
HO, DD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (01) :25-29
[10]   CLINICAL CORRELATES OF INVITRO HIV-1 RESISTANCE TO ZIDOVUDINE - RESULTS OF THE MULTICENTER CANADIAN AZT TRIAL [J].
MONTANER, JSG ;
SINGER, J ;
SCHECHTER, MT ;
RABOUD, JM ;
TSOUKAS, C ;
OSHAUGHNESSY, M ;
RUEDY, J ;
NAGAI, K ;
SALOMON, H ;
SPIRA, B ;
WAINBERG, MA .
AIDS, 1993, 7 (02) :189-196